Shares of Gaudium IVF and Women Health made a steady debut on the stock exchanges, listing at ₹83, which is about 5% higher than the issue price of ₹79 per share. The modest premium came as a positive signal for investors, particularly given cautious sentiment in segments of the broader market.
The company’s initial public offering (IPO), valued at approximately ₹165 crore, had drawn strong interest during the subscription window. Retail investors and high-net-worth individuals led the demand, resulting in the issue being subscribed multiple times over. The listing performance exceeded muted expectations in the grey market, where informal indications had suggested a flatter start.
Gaudium IVF operates in the assisted reproductive technology space, offering fertility treatments including in-vitro fertilisation (IVF). The company follows a hub-and-spoke operating model, with main centres supported by satellite clinics to widen patient reach. It currently runs centres across key urban markets and plans to deepen its footprint.
According to its stated plans, proceeds from the IPO will primarily be used to fund expansion, including the launch of new IVF centres in different parts of the country. A portion of the funds will also go toward debt reduction and general corporate purposes, strengthening the balance sheet as it scales operations.
The fertility services market in India has been expanding, driven by rising awareness, lifestyle changes, and improving access to specialised healthcare. Industry analysts believe organised players with established brands and clinical track records are well positioned to benefit from this structural growth trend.
Also Read: US halts use of Anthropic AI